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Objectives: A total of 4756 cases of intraaortic balloon pump Support have 
been recorded at the Massachusetts General Hospital since the first clinical 
insertion for cardiogenic shock in 1968. This report describes the patterns 
of intraaortic balloon use and associated outcomes over this time period. 
Methods: A retrospective r cord review was conducted. Results: Balloon use 
has increased to more than 300 cases a year at present. The practice of 
balloon placement for control of ischemia (2453 cases, 11.9% mortality) has 
become more frequent, whereas upport for hemodynamic decompensation 
qcongestive heart failure, hypotension, cardiogenic sbockl has been rela- 
tively constant 11760 cases. 38.2% mortality). Mean patient age has 
increased from 54 to 66 years, and mortality has fallen from 41% to 20%. 
Sixty-five percent I3097/4756) of the total patient population receiving 
balloon support underwent cardiac surgery. Placement before the operation 
(2038 patients) was associated with a lower mortality (13.6%) than intra- 
operative (771 patients. 35.7% mortality) or postoperative use (276 pa- 
tients, 35.9% mortality). Independent predictors of death with balloon 
pump support were insertion in the operating room or intensive care unit, 
transthoracic nsertion, age, procedure other than angioplasty or coronary 
artery bypass, and insertion for cardiogenic shock. Independent predictors 
of death with intraoperative balloon insertion were age, mitral valve 
replacement, prolonged cardiopulmonary bypass, urgent or emergency 
operation, preoperative renal dysfunction, complex ventricular ectopy, 
right ventricular failure, and emergency reinstitution of cardiopulmonary 
bypass. Conclusions: Balloons are being used more frequently for control of 
ischemia in more patients who are elderly with lower mortality. An 
institutional bias toward preoperative use of the balloon pump appears to 
be associated with improved outcomes. (J Thorac Cardiovasc Surg 1997: 
113:758-69) 
T he intraaortic balloon pump (IABP) represents a successful clinical application of the principle of 
counterpulsation. 1'2 IABP support can produce a 
modest increment in forward output in the injured 
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or failing heart, 3' 4 but the most obvious efficacy both 
theoretically and empirically is in the setting of 
ischemia resulting from coronary artery disease. 
With appropriate timing to the cardiac cycle, the 
IABP can both decrease cardiac work by deflating 
during systole and reduce afterload and augment 
coronary perfusion by inflating during diastole. This 
simultaneous improvement in coronary flow and 
reduction in myocardial oxygen consumption is a 
unique benefit of the !ABP and other methods of 
mechanical support. 
The first clinical experience with the IABP was in 
patients with cardiogenic shock after myocardial 
infarction. 5'6 Although outcomes were initially 
poor, with high mortality, significant hemodynamic 
improvement was documented, which encouraged 
continued investigation] In 1972, Buck!ey, Craven, 
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and Gold s reported 27 cases in which the IABP was 
used in patients unable to be weaned from cardio- 
pulmonary bypass by conventional means. Eighteen 
were weaned from the balloon, and 13 survived and 
were discharged from the hospital. In the 25 years 
since these initial reports nearly 5000 IABPs have 
been used at the Massachusetts General Hospital 
(MGH).  In this retrospective review we describe the 
evolution in indications, techniques, and results over 
this period. 
Patients and methods 
A total of 4756 cases of IABP insertion were registered 
in a log maintained by the cardiac procedures service. The 
hospital records of these patients were reviewed. The 
information abstracted from each record is shown in 
Appendix 1. The data fields were entered into a comput- 
erized database, prospectively since 1986 and retrospec- 
tively before that time. 
The population reviewed encompassed all patients who 
were supported by an IABP from 1968 to June 1995. A 
subset of these (3097) underwent a cardiac surgical pro- 
cedure during the same hospitalization. This cohort is 
referred to as the perioperativ e IABP group and includes 
patients in whom the balloon wa s placed before the 
operation (preoperative IABP), in the operating room 
during a cardiac surgical procedure (intraoperative 
IABP), or after the operation in the surgical intensive care 
unit (postoperative IABP). In a group of 193 consecutive 
patients who had intraoperative IABP insertions between 
1985 and 1993, a further data set (Appendix 2) was 
obtained retrospectively and analyzed. 
Multivariable probability models were constructed from 
the two sets of data with the use of BMDP program LR 
(BMDP Statistical Software, Inc, Los Angeles, Calif., 
Release 7, 1992). The candidate variables for the models 
are shown in Appendices 1 and 2. The purpose of these 
models was to describe the risk factors for the outcome 
predicted. Accordingly, a reference specifying standards 
for the use of such models was applied in the analyses. 9 
Each model was fit with a stepwise forward stepping 
algorithm with the asymptotic ovariance stimate used 
for entering variables into the model. In each step a 
variable was entered when the F statistic to enter the 
variable had a tail-probability value less than 0.01, and a 
variable was removed uring a step when the tail-proba- 
bility of the F statistic to remove was more than 0.05. 
Variables could enter or be removed twice from the 
model during the stepping. So that the data would not be 
overfitted, the stepping was stopped before the number of 
variables admitted into the model exceeded one tenth the 
number of events (deaths). To allow for nonconformity o
a linear gradient among predictor variables, the continu- 
ous variables were divided into a small number of cate- 
goric ranges chosen from cross-tabulations against actual 
mortality and from clinicians' judgment of ranges likely to 
have different rates; for example, age was recoded into 
three categories: age less than 70 years, age between 70 
and 80 years, and age more than 80 years. 
Pailwise interactions among all candidate variables 
were entered as candidate predictors according to the 
hierarchical rule available in the logistic regression pro- 
gram; that is, no interaction could be entered into the 
model unless its two underlying variables were already in 
the model. No such interactions were found in either of 
our models (all that would have satisfied the criteria for 
entry would have required overfitting of the model to 
enter). The coding of all predictor variables is shown in 
the two appendices or in Tables IV and V. The program 
LR tests for collinearity of pTedictor variables, either by 
failing to converge when collinear variables are selected 
into the model or by attempting to remove a variable if a 
collinear variable is selected into the model. We found no 
such cases in our models. The problem of influential outlier 
variables was addressed by reviewing numerous cross- 
tabulations of the data and by cross-checking the work of 
the data collection personnel. Data entry errors were 
caught and corrected in this manner. 
The mathematical fit of each model was checked with 
the use of the Hosmer-Lemeshow goodness of fit X 2 test in 
the LR program. No model was accepted unless the tail p 
value for this statistic was large (>0.2). In addition, the 
areas under the receiver operator characteristic curves for 
the models were compmed to assess the goodness of fit. 
For these models these are equivalent to the c-statistic or 
concordance index, the fraction of all pairs of patients, 
one survivor and one who died, for which the model 
predicted a higher probability of survival for the member 
of the pair who actually survived. 1° The receiver operator 
characteristic areas were 0.78 for the overall mortality 
model and 0.89 for mortality among 193 patients sup- 
ported with an IABP. Prospective validation of the prob- 
ability models remains to be carried out, although mod- 
eling among a small number of random subsets of the 
patients produced similar results. 
Results 
To illustrate changes in some of the patterns of 
use, we divided the data into 5-year intervals (Table I). 
During the period studied, average patient age 
increased from 54 to 66 years and the percent of 
patients older than age 70 years increased from 
2.1% to 38%. Despite this, mortality fell from 41% 
to 20%. The technique of insertion was initially 99% 
surgical via a femoral artery. In 1980 percutaneous 
insertion 11-13 was introduced, and in current prac- 
tice 97% of balloons are placed percutaneously. 
Throughout this period, there has been a small 
incidence (1.9%) of transthoracic balloon insertions 
via the ascending aorta when intraoperative balloon 
insertion is necessary and the femoral route in 
unsuccessful. 
As the technique of balloon insertion has changed 
from surgical to almost exclusively percutaneous, 
the major geographic location of insertion has 
shifted from the intensive care unit or operating 
room to the cardiac catheterization laboratory. In 
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Table I. Trends in IABP use divided into 5-year intervals (1968-1995) 
1968-75 1976-80 1981-85 1986-90 1991-95 Total 
Total 430 718 950 1211 !447 4756 
Mean age (yr) 54.5 57.8 59.9 63.1 65.7 61.7 
Percent older than 70 2.1 9.4 15.3 27.8 38.1 22.7 
Percent male 77.9 74.2 76.3 74.3 69.5 73.4 
Percent mortality 41.2 35.1 21.7 24.3 20,1 26 
Method (%) 
Surgical 99.7 93.2 28.2 8.3 2 31.4 
Percutaneous 0 1.8 69.2 91.2 96.5 66.7 
Transthoracic 0.2 5 2.6 0.5 1.5 1.9 
Location (%) 
Cath lab 2.1 6.7 64.6 75.1 82.7 58.4 
OR 25.1 42.8 23.7 14.5 11.9 20.8 
MICU 59.1 34 4.1 0.6 0 11.5 
SICU 9.8 9.9 4.1 5.1 4.6 5.9 
Percent cardiac surgery 73.3 84.5 69.5 60 54.5 65.1 
Percent PTCA 0 0 5.4 16.1 30.8 14.6 
Percent vascular complications 5.6 3.7 88 11.2 6.9 7.8 
OR, Operating room; MICU, medical intensive care unit; SICU, surgical intensive care unit; PTCA, percutaneous translnminal coronary angioplasty. 
Table II. Trends in indications for IABP 
Indication 1968- 75 1976-80 1981-85 1986-90 1991-95 Total 
Ischemia 122 243 493 649 946* 2453 
(%) (28.4%) (33.8%) (51.9%) (53.6%) (65.4%) (51.6%) 
Hemodynamic 251 382 349 442 336" 1760 
(%) (58.4%) (53.2%) (36.7%) (36.5%) (23.2%) (37.0%) 
Since 1975 the number of IABPs placed for hemodynamic decompensation (congestive heart failure, cardiogenic shock, or hypotension) has been relatively 
constant, whereas the number placed for ischemia has increased. 
*Data are up to June 1995, 7 months less than a full 5 years. 
Table III. Complications of lABP 
Percutaneous Transthoracic Surgical 
(3168) (90) (1493) 
Vascular 10.2% 0% 5.4% 
Infection 0.1% 0% 1.4% 
Balloon rupture/ 1.7% 4.4% 0.3% 
damage 
Passage failure 0.4% 3.3% 4.8% 
Complications of IABP use from 1968 to 1995 expressed as percent 
incidence. Infection for percutaneous IABP required positive blood cul- 
tures. In the surgical category, wound infections without positive bIood 
cultures were included. 
the past 5 years, 16% of balloons were placed in the 
operating room or intensive care unit as opposed to 
87% in the late 1970s. With this change, the insti- 
tution of IABP support has largely been transferred 
from the hands of the surgeon to those of the 
cardiologist. 
A total of 3097 patients underwent cardiac sur- 
gery before, after, or concomitant with IABP inser- 
tion. Perioperative IABP usage has declined as a 
percentage of all IABPs from a high of 84% to 54% 
in the most recent interval. The percentage of 
patients undergoing angioplasty has gone from 0% 
to 31%. MortalitY for patients receiving IABP sup- 
port and undergoing angioplast? T was 14.7%. 
Although the number of patients upported by an 
IABP for hemodynamic decompensation (conges- 
tive heart failure, hypotension, and cardiogenic 
shock) has been fairly constant, support for ongoing 
ischemia has become much more frequent (Table 
II). The logistic and technical simplicity of percuta- 
neous insertion had a major role in this trend. The 
mortality associated with IABP placement for isch- 
emia over the entire series was 11.9% and for 
hemodynamic decompensation, 38.2%. 
In Table III the incidence of complications for the 
series as a whole is summarized. Because of the 
nature of a retrospective r view, certain complica- 
tions, particularly passage failure with percutaneous 
IABP, may be underreported, Balloon rupture has 
been more frequent in the recent era and is strongly 
influenced by age, presumably because of the in- 
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Table IV. Multivariate predictors of death in all patients (medical and surgical) supported by an IABP from 
1968 to 1995 
Odds ratio 95% lower 95% upper 
Multivariable predictors (OR) OR boundary OR boundary 
Location 
CCL (other risks relative to CCL) 1 
Operating room 1.7 1.3 2.2 
Medical ICU 1.8 1.3 2.5 
Surgical ICU 1.7 1.2 2.3 
Other 2.7 1.1 6.7 
Outside hospital 1 0.6 1.6 
Method 
Surgical/graft (risk relative to this) 1 
Surgical/no graft 1.2 0.8 1.7 
Percutaneous 0.8 0.6 1 
Percutaneous through graft 2 0.7 5.9 
Transthoracic 2.9 1.8 4.6 
Age 
Age < 70 1 
70 -< age < 80 1.9 1.6 2.3 
Age -> 80 3.2 2.1 4.8 
Procedure (risk relative to all other procedures) 
Coronary artery bypass grafting 0.5 0.4 0.6 
Other 2 1.4 2.7 
Percutaneous transcoronary angioplasty 0.6 0.4 0.7 
Indications (risk relative to all other indications) 
Ongoing ischemia 0.5 0.4 0.6 
Myocardial infarction 1.6 1.3 2 
Ventricular tachycardia/fibriltation 2 1.6 2.5 
Cardiogenic shock 2.8 2.3 3.3 
Congestive heart failure 1.8 1.4 2.3 
CCL, Cardiac atheterization laboratory; ICU, intensive care unit. 
creasing severity of calcific aortic atherosclerosis in 
older patients. 
The independent predictors of mortality for all 
patients upported by IABP are shown in Table IV. 
Notable among these were insertion of the IABP in 
the operating room or intensive care unit, transtho- 
racic insertion, age, procedure other than coronary 
artery bypass grafting or angioplasty, and insertion 
for cardiogenic shock. Placement for ongoing isch- 
emia and for associated coronary artery bypass 
grafting or angioplasty were associated indepen- 
dently with a better outcome. 
The results of the multivariate analysis of pre- 
dictors of mortality in 193 intraoperative IABP 
insertions are shown in Table V. Mortality was 
32% during this interval, slightly less than the 
35.7% mortality for intraoperative insertion in the 
entire series. The independent predictors of death 
in these patients were age, mitral valve replace- 
ment, prolonged cardiopulmonary bypass, urgent 
or emergency operation, preoperative renal dys- 
function, and complex ventricular ectopy or right 
ventricular failure after crossclamp removal. The 
timing of IABP insertion was important: place- 
ment after separation from bypass was associated 
with a better outcome than placement o wean 
from bypass; the outcome of placement after 
emergency reinstitution of bypass was worse. 
Postoperative acidosis and oliguria were associ- 
ated with a higher risk of death. 
Discussion 
The evolution of demographics and practice ob- 
served conform with generalized trends throughout 
medicine toward improved results with less invasive 
treatment of more patients who are elderly. 
There are two areas in which the data may be 
misleading. The first is the reduction in mortality 
observed over time despite the increasing age of the 
population. Some of this might reflect advances in 
critical care, surgery, and anesthesia s well as the 
inception of angioplasty, but there has also undoubt- 
edly been a change in indications for IABP support 
such that the patients who are receiving IABP 
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Table V. Multivariate predictors of death with IABP insertion during 193 cardiac surgical procedures between 
1985 and 1993 
Odds ratio 95% lower 95% upper 
Multivariable predictors (OR) OR boundary OR boundary 
Intraoperative IABP insertion timing 
Necessary to come off CPB initially (risks relative to this) 
Emergency reinstitution of CPB for instability 
Off CPB before chest closure 
Off CPB after chest closure 
Preoperative assessment 
Operation elective (risk relative to this) 
Operation urgent/emergency 
Procedure (risk relative to all other procedures) 
Mitral valve replacement 
CPB time (min) 
Time < 100 (risks relative to this) 
100 -< time < 150 
Time -> 150 
Preoperative creatinine 
Creatinine < 1.5 (risks relative to this) 
1.5 <- Creatinine < 2.0 
Creatinine -> 2.0 
Intraoperative CPB weaning problems* 
Right ventricular dysfunction 
Complex ventricular ectopy 
1 
6.3 1.7 24 
0.2 0.06 0.8 
2.8 0.8 10 
1 
4.2 
6.3 
1.7 10.2 
1.8 22 
1 
6.6 0.9 49 
19 2.4 147 
1 
4.8 1.5 16 
6.2 1.8 21 
11 2.5 47 
15 2.9 80 
CPB, Cardiopulmonary b pass. 
*Relative to all other problems and no problems. 
support at the present time represent a less sick 
population (see Table II). 
Second, there was an apparent increase in vascu- 
lar complications with the introduction of percuta- 
neous insertion in 1980 (see Table I). Whether this 
represents a true change in morbidity is question- 
able. For the purpose of this tabulation, vascular 
complications were defined as cases in which surgi- 
cal treatment was required for limb ischemia, bleed- 
ing, or vessel injury. Mesenteric infarction, amputa- 
tion, and aortic dissection were also included. Limb 
ischemia that resolved with balloon removal and 
localized arterial injury that did not require surgery 
were not included. This is a relatively narrow defi- 
nition of vascular complications and probably un- 
derstates their incidence compared with that re- 
ported in other series, u-17 With the change from 
surgical to percutaneous IABP insertion there was 
an immediate major reduction in the number of 
groin operations done overall, because a surgical 
balloon by definition requires an operation to place 
and remove the device whereas percutaneous inser- 
tion requires urgery only when there is a complica- 
tion. More than 90% of percutaneous balloons are 
removed without the need for surgery, and the 
majority of vascular surgical procedures after per- 
cutaneous balloon removal are simple thrombecto- 
mies or patch angioplasties of no greater magnitude 
than surgical balloon placement or removal. Cata- 
strophic vascular complications (iliac or aortic per- 
foration, mesenteric nfarction, amputation) have re- 
mained at less than 1% throughout the series after 
initially appearing to be more frequent with the first 
100 balloons placed by the percutaneous technique.17 
In recent years, surgical series from St. Louis 
University and Washington Universi@ 8' 19 have re- 
ported institutional patterns of IABP use and asso- 
ciated mortality. In Table VI the last 15 years of our 
data on perioperative IABP use at the MGH are 
displayed with data from these other series. The rate 
of IABP use as a percentage of all cardiac opera- 
tions was higher at the MGH: 12.3% versus 8.5 and 
9.8%. A higher percentage ofperioperative balloons 
were placed before the operation in our series (70.6% 
vs 35.7% and 18.8% of perioperative balloons). Intra- 
operative and postoperative IABP use was corre- 
spondingly less frequent at the MGH (3.6% of all 
cardiac operations vs 6.3% and 6.8%). This strong bias 
toward early balloon insertion is an established tenet 
of cardiology practice at the MGH because the deci- 
sion to place a balloon more frequently occurs at the 
time of catheterization before surgical consultation. 
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Cardiovascular Surgery 
Volume 113, Number 4 
Torchiana et aL 7 6 3 
Table VI. Comparison with other surgical series 
Percent operations Percent of periop. Percent mortality 
Cardiac with periop. IABP placed for all periop. 
Institution operations IABP preop. IABP 
MGH (1980-95) 17,678 2175 1535 16.3% 
(12.3%) (70.6%) (95% CI: 14.7% to 17.9%) 
Washington Univ. (1986-91) 6,856 672 240 28.7% 
(9.8%) (35.7%) (95% CI: 25.3% to 32.1%) 
St Louis Univ. (1982-90) 6,877 580 107 44.0% 
(8.5%) (18.4%) (95% CI: 40% to 48%) 
At MGH, a higher percentage of cardiac surgical cases had an IABP. A greater percentage of these IABPs were placed preoperatively. (Comparison made 
by X 2 tests with two degrees of freedom). CI, confidence interval. 
Table VII. Outcomes with perioperative IABP in the percutaneous era (mortality since 1980) 
Cath lab OR SICU Total 
Number of patients 1168 435 198 2175 
Deaths 117 128 66 354 
Mortality rate t0.0% 29.4% 33.3% 16.3% 
(95% CI: 8.3% to 11.7%) (95% CI: 25% to 33.8%) (95% CI: 27% to 40%) (95% CI: 14.7% to 17.9%) 
The mortality rate of preoperative IABP usage was one third that of an intraoperative or postoperative IABP. OR, Operating room; SICU, surgical intensive 
care unit; C/, confidence interval. 
Although the association cannot be proved to be 
causal, the mortality associated with this practice is 
lower (16.3% vs 28.7% and 44.0%), and it is our 
impression that liberal use of IABP support to 
stabilize medically refractory ischemia in the preop- 
erative interval reduces overall surgical mortality 
(Table VII). Our preference has been to allow 24 to 
48 hours of IABP support to quiet unstable or 
postinfarction angina and permit recovery of isch- 
emic myocardium before operation as opposed to 
undertaking an immediate operation in the setting 
of ongoing ischemia. Persistent angina, hemody- 
namic instability, or limb-threatening ischemia in 
the leg into which the balloon was inserted may still 
necessitate an emergency operation in some in- 
stances. Others 2° have noted the efficacy of early 
IABP therapy in surgical patients with unstable 
coronary syndromes. A reduction in mortality in 
patients having emergency/urgent coronary bypass 
grafting from 31% to 0% was associated with an 
increase in preoperative IABP use from 24% to 
89% of these cases. 
It is possible that the lower mortality associated 
with preoperative balloon use may reflect a propen- 
sity to use IABP support prophylactically in stable 
patients with high-risk anatomy. This can have only 
a modest influence, because just 7% of our periop- 
erative insertions ince 1980 have been prophylactic, 
with an 11% mortality rate, which is not lower than 
that of other patients receiving preoperative IABP 
support. Finally, it is unlikely that these results can 
be attributed to recent advances in myocardial pro- 
tection, because the techniques used at the MGH in 
the cases reported are a mixture of the spectrum of 
methods through the history of cardiac surgery, 
including hypothermic fibrillatory arrest, crystalloid 
cardioplegia, cold blood cardioplegia, and warm 
continuous blood cardioplegia. 
Given that one of the areas in which mortality 
remains highest is the subgroup of patients under- 
going balloon insertion during and after heart sur- 
gery, it is logical to ask whether intervention with a 
ventricular assist device (VAD) in some of these 
patients might produce a better outcome. Previous 
attempts21.22 at determining which patients are at 
greatest risk of death with intraoperative IABP 
insertion include a prospectively validated model 
developed by Baldwin, Slogoff, and Noon. 22 Their 
model describes the need for pacing, preoperative 
renal dysfunction, advanced age, female sex, and 
prolonged cardiopulmonary b pass as positive pre- 
dictors of death. Our analysis had similar findings 
although sex was not found to be an independent 
predictor. Among the other variables we found not 
to be predictive of mortality with IABP insertion 
were preoperative or postoperative myocardial in- 
farction, number or dose of inotropic agents, preop- 
erative left ventricular function, cardiac output be- 
fore or after the operation, peripheral vascular 
disease, diabetes, reoperation, and left main disease. 
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The independent predictors of death with intra- 
operative insertion shown in Table V can be com- 
bined into a prediction formula that has an 80% 
sensitivity and specificity in this retrospective popu- 
lation but has not been prospectively validated. The 
practical usefulness of such a model is limited in that 
some of the predictive lements are generalized risk 
factors for death after heart surgery and do not 
clarify which portion of the population at risk is 
most likely to be salvaged by VAD support. For 
example, elderly patients with prior renal dysfunc- 
tion and long bypass runs may be just as likely to do 
poorly with VAD support as with an IABP. Ideally, 
we would like to be able to identify the subgroup of 
patients who are both at high risk of death with 
IABP and have the best likelihood of survival with a 
VAD. 
Theoretically, the subset of patients that would be 
best served by temporary VAD support are those 
with profound hemodynamic ompromise but a 
technically corrective cardiac operation with revers- 
ible injury. In our limited institutional experience, 
14 patients were supported with a VAD after car- 
diac operations between 1986 and 1995. Four were 
successfully bridged to transplantation, and three of 
these survived. A fifth patient was weaned from the 
VAD and is a long-term survivor. As experience 
with VAD support after cardiotomy is acquired in 
greater numbers, the question can be addressed 
more substantially. 
In conclusion, the use of IABP support has 
steadily become more prevalent although still with a 
significant associated mortality and complication 
rate. The data presented are limited by being un- 
controlled and retrospective, but it is our impression 
that liberal preoperative balloon use to quiet unsta- 
ble coronary syndromes can reduce surgical mortal- 
ity and the need for IABP placement during and 
after the operation. The risk of death with IABP use 
remains high, but models to predict death in this 
setting may not identify the best candidates for 
VAD support. 
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Discussion 
Dr. D. Glenn Pennington (Winston-Salem, N.C.). Dr. 
Torchiana and his colleagues at the MGH have presented 
a superb report of one of the oldest and largest IABP 
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experiences in the world, and they have demonstrated an 
encouraging decline in the overall mortality and vascular 
complication rate. Furthermore, their criteria for use 
indicate a dramatic decrease in the hemodynamic ndica- 
tion and a sharp increase in the indication for unstable 
angina, a fact that probably accounts for most of the 
improvement in the mortality rate. 
Our interest centers more around the group of patients 
who required IABPs in conjunction with cardiac surgery. 
The authors report a higher frequency of perioperative 
use, 12%, than most other centers. Moreover, more than 
70% of the cardiac surgery IABPs were placed before the 
patient was taken to the operating room. We assume that 
most 0f those patients were not in cardiogenic shock and 
had balloons placed prophylactically or to stabilize unsta- 
ble angina. Might some of these patients without hemo- 
dynamic compromise have done just as well without a 
balloon? However, hemodynamic stabilization of patients 
before coming to the operating room makes inherently 
good sense, and this practice has probably been under- 
used in many of our centers. We are indebted to the MGH 
group for bringing this to our attention. 
Because a large number of our patients are currently 
referred for unstable angina, I wish to ask what criteria 
should be used in a patient group with such wide varia- 
tions. If every patient with so-called unstable angina 
received an IABP before the operation, the cost would 
become significant. 
In the last subset of patients analyzed, there are 193 
patients who did receive their balloons in the operating 
room or intensive care unit. In this group the 32% 
mortality rate was more in keeping with that reported 
from other centers. The authors tried to determine 
whether VADs might have been more helpful than IABPs 
in this group, and they could project a potential 40% 
survival in this group if they had received VADs. Perhaps 
that would be significant. In any case, I believe that the 
32% mortality rate in patients requiring operative IABP 
placement is still unacceptable and that we are obligated 
to evaluate the effect of a more complete form of circu- 
latory support, such as a VAD, in these desperately ill
patients. 
I would put forward four questions. One, how many of 
the patients without hemodynamic ompromise might 
have done well without IABPs? Two, which patients with 
unstable angina should receive preoperative IABPs? 
Three, what role should VADs play? Four, would the 
authors upport a randomized study of IABP versus VAD 
for patients requiring intraoperative support for hemody- 
namic compromise? 
Dr. Torchiana. I would like to thank Dr. Pennington for 
his questions. The answers to these questions are a matter 
of opinion and practice rather than a matter of definitive 
fact. I think the fact that the percentage of balloons used 
at MGH is around a quarter to a third higher than at other 
comparabie nstitutions but the mortality rate significantly 
lower suggests that we are not overusing balloons, but, 
rather, that they are being underused in the preoperative 
period at other institutions. Undoubtedly, a certain per- 
centage of patients brought o the operating room at our 
institution with a preoperative 1ABP did not need to have 
it placed. However, prophylactic use is not a major 
indication for balloon use at our institution, because only 
7% of the patients in this report had prophylactic bal- 
loons. 
In general, the major use of the balloon was for the 
stabilization of unstable angina. These are patients in 
whom angina cannot be controlled by intravenous nitro- 
glycerin and other attempts at medical therapy. If a 
balloon is placed in these patients and the angina sub- 
sides, it is our conviction that allowing the patient 24 to 48 
hours of IABP support rather than an immediate opera- 
tion is preferable. 
Which patients might best be benefited by a VAD 
insertion in the operating room is a difficult question. 
When you identify the patients most likely to die with an 
IABP insertion, you have really identified a very sick 
group of patients who are unlikely to do well with a VAD 
either. The most logical way to approach this, as Dr. 
Pennington suggests, is to randomize the insertion of an 
IABP or a VAD in this group. 
Dr. Robert A. Guyton (Atlanta, Ga.). I lived in the 
MGH from 1970 until 1980 and think that I have probably 
inserted 100 or so of these balloons. My question has to do 
with the patients who had balloons inserted who did not 
come to the operating room. You report between 1980 
and the present a 16% mortality in patients who were 
operated on with IABP support, but you report about a 
21% mortality overall for balloon usage. That means that 
the mortality of the patients who had the balloon inserted 
and did not go to the operating room must be 30% or 
35%. Did patients, for example, who had a major catas- 
trophe at the time of IABP insertion in the preoperative 
period not get operated on and therefore not enter into 
the numerator of your perioperative deaths of patients 
with IAPBs? 
Dr. Torehiana. That is an excellent point, Dr. Guyton, 
and I do not think there is any way that I can prove or 
refute what you are saying. The patients in whom a 
balloon is placed who do not respond with relief of 
ischemia or patients in whom a balloon is placed for an 
acute mechanical complication of myocardial infarction, 
like papillary muscle rupture or postinfarction ventricular 
septal defect, go immediately to the operating room, as do 
patients with a balloon in an ischemic limb. Those groups 
are not turned away from surgical treatment. However, I
agree that it is possible that surgical selection is at play 
and some patients who receive an IABP and do very, very 
badly therefore die without surgical treatment. Yours is a 
valid observation and probably may still be the correct way 
to do things. Not all patients in whom a balloon is placed 
are candidates for surgery. 
For appendixes see pages 766-9. 
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Append ix  1. Data form for all balloon insertions, 1968 to 1995 
Field names and entry options 
LOCATION 
1 Cardiac catheterization laboratory 
2 Operating room 
3 Medical intensive care unit 
4 Surgical intensive care unit 
5 Emergency ward 
6 Other 
7 Outside hospital 
INSERTION SITE 
1 Left femoral 
2 Right femoral 
3 Transthoracic 
4 Other 
SEX 
1 Male 
2 Female 
SUCCESS 
1 Yes 
0 No 
CATHETER SIZE 
1 9F 
2 95F 
3 10.5F 
4 l lF  
5 12F 
6 14F 
IABP SIZE 
1 40 ml 
2 30 ml 
3 20 ml 
MANUFACTURER 
1 AVCO/Kontron 
2 Aires/St. Jude Medical 
3 Datascope 
4 Mansfield 
5 Other 
PREVIOUS IABP 
1 Yes 
0 No 
AORTOILIAC ANGIOGRAM 
I Yes 
0 No 
DEATH 
1 Yes 
0 No 
METHOD 
1 Surgical graft 
2 Surgical/no graft 
3 Percutaneous 
4 Percutaneous through graft 
PROCEDURE 
01 Coronary bypass 
02 Mitral valve replacement or repair 
03 Aortic valve replacement 
04 Tricuspid valve replacement or repair 
07 Reoperation 
08 Other 
05 Left ventricular aneurysmectomy 
06 Repair ventricalar septal rupture 
09 Percutaneous transluminal coronary angioplasb, 
10 Percutaneous aortic valvuloplasty 
11 Percutaneous mitral valvuloplasty 
INDICATION 
01 Support in cardiac atheterization laboratory 
02 Support after cardiopulmonary b pass 
03 Ongoing ischemia 
04 Myocardial infarction 
05 Ventricular septal rupture 
06 Mitral regurgitation 
07 Ventricular arrhythmias 
08 Prophylactic 
09 Hypotension 
10 Cardiogenic shock 
11 Congestive heart failure 
INSERTION TIMING 
l Before catheterization 
2 During catheterization 
3 After catheterization 
4 Preoperative 
5 Intraoperative 
6 Postoperative 
7 IABP only 
COMPLICATION 
01 Perforation of arterial wall 
02 Dissection of local artery 
03 Passag e failure 
04 Bleeding at insert site 
05 Infection at insert site 
06 Infection with positive blood culture 
07 Embolus 
08 Balloon rupture 
09 Damage to IABP catheter 
10 Loss of pulse, IABP removal 
11 Loss of pulse, vascular surgery after removal 
13 Arteriovenous fi tula 
14 Loss of limb 
15 False aneurysm 
16 Iliac perforation 
17 Laceration 
18 Mesenteric nfarction 
19 Thrombosis 
20 Above-knee amputation 
21 Below-knee amputation 
22 Other 
CAUSE OF DEATH 
1 Myocardial infarction 
2 Congestive heart failure 
3 Arrhythmia 
4 Noncardiac 
TIMING OF DEATH 
1 Before catheterization 
2 During catheterization 
3 After catheterization 
4 Preoperative 
5 Intraoperative 
6 Postoperative 
7 After IABP 
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Appendix 2. IABP  insertion data fo rm 
Field name Entry option 
Sex 
Age 
Intraoperative CPB weaning problems 
Intraoperative r ason for IABP 
Intraoperative IABP insert iming 
Postoperative myocardial infarction 
Postoperative metabolic function > 1 
Bicarbonate infirst 8 hours in intensive care unit 
Postoperative r nal function 
Postoperative pulmonary function 
Admit date 
Discharge date 
Surgery date 
IABP removal date 
Surgeon 
Mortality 
IABP route 
Status at surgery 
Preoperative l ft ventricular function 
Preoperative ejection fraction 
Preoperative cardiac output 
Preoperative cardiac index 
Torchiana et al. 7 6 7 
Normal 
Oliguria/anuria (<30 ml/hr for >2 hr consecutively) 
Normal 
Hypoxemia (Po 2 <100 on 100% Fi%) 
Percutaneous femoral 
Surgical femoral 
Transthoracic 
Elective 
Emergency 
Urgent 
Normal 
Isolated ysfunctional region 
Diffuse mild/moderate hypokinesis 
Severe dysfunction 
Properative pulmonary capillary wedge pressure 
Preoperative condition Unremarkable 
Myocardial infarction <7 days 
Ischemia <24 hr preop. 
Cardiopulmonary resuscitation  arrival in operating 
room 
Pressor use before operating room 
Intravenous heparin 
Intravenous nitroglycerin 
Diuretic need 
Myocardial infarction 7-30 days 
Appendix 2continued on next page. 
Low resistance state 
Left ventricular dysfunction 
Right ventricular dysfunction 
Rhythm dysfunction 
Valvular dysfunction 
Complex ventricular ectopy 
Atrial conduction abnormality 
Electrocardiographic ischemic hanges 
Low resistance state 
Left ventricular dysfunction 
Right ventricular dysfunction 
Rhythm dysfunction 
Valvular dysfunction 
Complex ventricular ectopy 
Atrial conduction abnormality 
Electrocardiographic ischemic hanges 
Necessary tocome off CPB initially 
Emergency reinstitution ofCPB for instability 
Off CPB before chest closure 
Off CPB after chest closure 
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Appendix 2. Continued 
Prebypass events 
Field name Entry option 
Technical comments 
CPB time 
Crossclamp time 
Bypass eparation attempts 
Surgical procedure, reoperation 
Surgical procedure, coronary bypass 
Surgical procedure, number of distals 
Surgical procedure, aortic valve replacement 
Surgical procedure, mitral valve replacement 
Surgical procedure, left ventricular aneurysmectomy 
Myocardial infarction >30 days 
Peripheral vascular disease 
Diabetes 
Active angina 
Cigarette use 
Carotid disease/known stroke 
Congestive heart failure 
Smooth course 
Hypotension 
Arrhythmia 
ST segment changes 
Bleeding/hypovolemia 
Low cardiac output 
Redo with graft trauma 
Poor distal vessels/flow 
Unavailable/poor conduit 
Retrograde cardioplegia 
Inadequate protection 
Bad aorta 
Other 
Patient weight in kilograms 
Surgical ICU pressors 
ICU hemodynamics, pulmonary artery systolic 
ICU hemodynamics, pulmonary artery diastolic 
ICU hemodynamics, left atrial pressors 
ICU hemodynamics, mean artery pressor 
Levophed 
Dopamine 
Dobutamine 
Epinephrine 
Amrinone 
Isuprel 
ICU hemodynamics, pulmonary capillary wedge pressure 
ICU hemodynamics, entral venous pressure 
ICU hemodynamics, ardiac output 
ICU hemodynamics, ardiac index 
Preoperative l ft ventricular end-diastolic pressure 
Preoperative coronary artery disease, No. of diseased vessels 
Preoperative Coronary artery disease, left main 
Preoperative coronary artery disease, patient diseased graft 
Preoperative alve function, aortic stenosis 
Preoperative alve function, aortic insufficiency 
Preoperative alve function, mitral stenosis 
Preoperative alve function, mitral regurgitation 
Preoperative alve function, aortic stenosis degree 
Preoperative alve function, aortic insufficiency degree 
Trace 
Mild/moderate 
Severe 
Trace 
Mild/moderate 
Severe 
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Appendix 2. Continued 
FieM name Entry option 
Preoperative alve function, mitral regurgitation degree 
IABP removal complication, bleeding 
IABP removal complication, vascular surgery 
Preoperative creatinine 
Trace 
Mild/moderate 
Severe 
CPB, Cardiopulmonary bypass; ICU, intensive care unit. 
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